News Search Results
Sep 08, 2023, 09:00 ET Kyverna Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline
More news about: Kyverna Therapeutics
Sep 07, 2023, 16:00 ET Verily and Kyverna Therapeutics Announce Collaboration to Advance Cell Therapy for Autoimmune Diseases
a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline
More news about: Kyverna Therapeutics
Sep 05, 2023, 03:00 ET ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement
of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. ERS holds over 100 patents worldwide. For additional information, please visit
More news about: ERS Genomics
Aug 31, 2023, 07:01 ET Exacta Bioscience and Ginkgo Bioworks Announce Partnership to Optimize Exacta's Crop Protection Product
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19
More news about: Ginkgo Bioworks
Aug 29, 2023, 09:52 ET CCM Biosciences Launches from Stealth to Advance Portfolio of Proprietary, First-in-Class Therapies and Companion Diagnostic Tests Across Multiple Therapeutic Areas
Biosciences based on technology platforms he developed in academia in the areas of chemical biology, computational biophysics, systems biology, and synthetic biology. These platforms, which merge experimental high-throughput screening with physics-based computational methods and learning algorithms, have been
More news about: CCM Biosciences
Aug 29, 2023, 08:00 ET Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity
Vertex AI platform across genomics, protein function, and synthetic biology, helping Ginkgo's customers accelerate innovation and discovery in fields as diverse as drug discovery, agriculture, industrial manufacturing,
More news about: Ginkgo Bioworks
Aug 24, 2023, 08:01 ET Antheia Achieves Major Commercial Milestone
Antheia was founded on the belief that synthetic biology can be leveraged to produce highly complex pharmaceutical molecules at commercial scale with greater efficiency than current approaches. Many
More news about: Antheia
Aug 24, 2023, 07:00 ET Concentric by Ginkgo and CGIAR International Livestock Research Institute (ILRI) announce collaboration on pathogen surveillance
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Aug 24, 2023, 06:00 ET Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies
development timelines by up to 10 months. "bit.bio is the leading synthetic biology company focussed on human cells. We are thrilled to deepen our partnership with bit.bio to facilitate a leap forward in the development of synthetic biology-based cell therapies," said Paul Dabrowski,
More news about: Synthego
Aug 17, 2023, 08:00 ET Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS
the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS),
More news about: Bloom Science
Aug 11, 2023, 19:00 ET Global Synthetic Biology Market to grow by USD 28,253.12 million between 2022 and 2027 | The growing application of synthetic biology drives the market
and acquisitions, geographical expansion, and product launches, to enhance their presence and competitiveness in Global Synthetic Biology Market. The Global Synthetic Biology Market is driven by its diverse applications across industries and the potential to address pressing challenges such as
More news about: Technavio
Aug 10, 2023, 08:00 ET ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing Agreement
of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. ERS holds over 100 patents worldwide. For additional information, please visit www.ersgenomics.com
More news about: ERS Genomics
Aug 10, 2023, 06:30 ET Animal Genetics Market worth $9.5 billion | MarketsandMarkets
biotechnology, and data analytics. This industry will witness the emergence of cutting-edge techniques such as precision breeding, gene editing, and synthetic biology, enabling the tailored enhancement of livestock traits for improved productivity, disease resistance, and environmental sustainability. Ethical
More news about: MarketsandMarkets
Aug 09, 2023, 21:38 ET AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION
and vendors during the process. "Since its founding 20 years ago, Amyris has been a pioneer in the development of ingredients made with synthetic biology and has enjoyed great commercial success, particularly as a result of our innovative Lab-to-Market™ technology platform, proven ability to rapidly
More news about: Amyris, Inc.
Aug 09, 2023, 17:01 ET Ginkgo Bioworks Reports Second Quarter 2023 Financial Results
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Aug 07, 2023, 07:01 ET Ginkgo Bioworks Announces Collaboration with Merck to Improve Biologic Manufacturing
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19
More news about: Ginkgo Bioworks
Aug 03, 2023, 08:00 ET ERS Genomics & Transomic Technologies enter into CRISPR/Cas9 Licensing Agreement
of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. ERS holds over 100 patents worldwide. For additional information, please visit www.ersgenomics.com
More news about: ERS Genomics
Aug 03, 2023, 07:30 ET BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies
LinkedIn About bit.biobit.bio is a synthetic biology company focused on human cells that is advancing medicine (UN SDG9) and enabling curative treatments (UN SDG3). The company does this by industrializing
More news about: BlueRock Therapeutics
Aug 03, 2023, 07:30 ET BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies
LinkedIn About bit.biobit.bio is a synthetic biology company focused on human cells that is advancing medicine (UN SDG9) and enabling curative treatments (UN SDG3). The company does this by industrializing
More news about: BlueRock Therapeutics
Aug 03, 2023, 07:00 ET Shenzhen to Foster Quantitative Biology Stronghold
research including synthetic biology," said LIU at the opening ceremony of the conference. Synthetic biology has its interdisciplinary nature and it's important in advancing our understanding of life's fundamental principles. "Synthetic biology has potential applications
More news about: Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences
Aug 03, 2023, 07:00 ET Ginkgo Bioworks and the Government of the Republic of Panama Announce Plans to Establish New Biosecurity Capabilities
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19
More news about: Ginkgo Bioworks
Aug 03, 2023, 05:00 ET Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
mission of engineering a new class of therapies for autoimmune diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline
More news about: Kyverna Therapeutics
Aug 02, 2023, 09:00 ET Elo Life Systems Appoints Alan Berry as Chief Scientific Officer & Matt Roszell as Senior Vice President, Communications and Corporate Affairs
brings more than 30 years of synthetic biology expertise and R&D leadership across startups and multinational companies. "Elo is pushing the boundaries of what's possible, using plants to unlock new avenues that were previously unavailable through other synthetic biology platforms," said Berry.
More news about: Elo Life Systems
Aug 02, 2023, 08:55 ET The Foundry Joins Asimov to Create a New R&D Center for Genetic Design
BOSTON, Aug. 2, 2023 /PRNewswire/ -- Asimov, the synthetic biology company building tools to design living systems, announced today that The Foundry, previously of MIT and the Broad
More news about: Asimov